Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

著者: Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim Papp, Howard Sofen, L. Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin Valdes, Elizabeth H. Thompson, H. Bachelez - The Lancet 2018 被引用: 662